Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest beta-thalassemia Stories

2014-01-09 08:26:57

--Partnership to Focus on Developing Novel Therapies for Sickle Cell Disease and Beta-Thalassemia-- CAMBRIDGE, Mass. and RICHMOND, Calif., Jan. 9, 2014 /PRNewswire/ -- Biogen Idec (NASDAQ:BIIB) and Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. The...

2014-01-08 08:27:43

RICHMOND, Calif., Jan. 8, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will present an update on Sangamo's clinical and preclinical ZFP Therapeutic(®) programs and upcoming milestones, as well as an overview of the Company's business strategy at the 32(nd) Annual J.P. Morgan Healthcare Conference on Thursday, January 16(th) at 11:00 am PT in San Francisco. (Logo:...

2013-12-09 14:00:42

New research presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans uncovers several important insights into the pathophysiology of sickle cell disease and thalassemia that may soon translate into the development of better, more targeted treatments for hundreds of thousands of patients worldwide. Sickle cell disease (SCD) is an inherited, chronic disorder affecting nearly 100,000 Americans. Instead of producing healthy red blood cells,...

2013-12-09 08:27:37

Novel Genome-Editing Approach Offers a Potential Cure for Both Diseases RICHMOND, Calif., Dec. 9, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of preclinical data from its ZFP Therapeutic program for the treatment and potential cure of both sickle cell disease (SCD) and beta-thalassemia. The data demonstrate that Sangamo's approach, using its proprietary and highly specific zinc finger nuclease (ZFN) gene-editing technology, enables...

2013-11-20 16:26:51

RICHMOND, Calif., Nov. 20, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that seven abstracts have been accepted for presentation at the 55(th) annual meeting of the American Society of Hematology (ASH), which will be held December 7-10, 2013, in New Orleans, LA. (Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO) "ASH provides an outstanding forum to highlight our advancing pre-clinical IND-candidate programs," said Edward Lanphier, Sangamo's...

2013-11-04 14:11:33

In-depth look at living with thalassemia A CHEO-led multi-site North American study, headed by Dr. Robert Klaassen, lead investigator at CHEO and associate professor in the University of Ottawa's Department of Pediatrics, has confirmed the validity and reliability of a quality of life measurement tool for children and adults with thalassemia major. The tool was created between 2006 and 2009 through the combined efforts of CHEO, the Hospital for SickKids and Laurentian University....

2013-06-10 08:30:34

SAN DIEGO, June 10, 2013 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized, double-blind, placebo-controlled Phase 2b study of HQK-1001 in patients with sickle cell disease. The study, initiated in July 2012, enrolled a total of 77 patients in clinical sites in the US, Canada, Jamaica, Egypt and Lebanon. HemaQuest...

2013-05-24 08:22:36

Funding for IND Application and Clinical Trial of Novel and Potentially Curative Approach RICHMOND, Calif., May 24, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted the Company a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia based on the application of its zinc finger nuclease (ZFN) gene-editing technology in hematopoietic...

2013-01-23 16:24:31

EAST HANOVER, N.J., January 23, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Exjade(®) (deferasirox) for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration of at least 5 mg of iron per gram dry weight and a serum ferritin measurement greater than 300 micrograms per liter. Exjade is the first treatment...

2012-12-06 16:23:52

NEW YORK, Dec. 6, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), announced that the company is providing an update on its technology platform advancements and pipeline of ZFP Therapeutics(®) as well as near- and mid-term operating goals during an Analyst and Investor Briefing being held today in New York City. The presentation, by members of Sangamo management team, will be webcast live beginning at 5:00 pm ET and can be accessed via a link on the Company's...